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Association Between Cytokines
and Liver Histology in Children with
Nonalcoholic Fatty Liver Disease
Emily R. Perito,1 Veeral Ajmera,1 Nathan M. Bass,1 Philip Rosenthal,1 Joel E. Lavine,2 Jeffrey B. Schwimmer,3
Katherine P. Yates,4 Anna Mae Diehl,5 Jean P. Molleston,6 Karen F. Murray,7 Ann Scheimann,8 Ryan Gill,1
David Glidden,1 and Bradley Aouizerat,1,8 Nonalcoholic Steatohepatitis Clinical Research Network
Reliable noninvasive markers to characterize inflammation, hepatocellular ballooning, and fibrosis in nonalcoholic fatty
liver disease (NAFLD) are lacking. We investigated the relationship between plasma cytokine levels and features of
NAFLD histology to gain insight into cellular pathways driving nonalcoholic steatohepatitis (NASH) and to identify
potential noninvasive discriminators of NAFLD severity and pattern. Cytokines were measured from plasma obtained at
enrollment in pediatric participants in NASH Clinical Research Network studies with liver biopsy-proven NAFLD. Cyto-
kines were chosen a priori as possible discriminators of NASH and its components. Minimization of Akaike information
criterion was used to determine cytokines retained in multivariable models. Of 235 subjects, 31% had “Definite NASH”
on liver histology, 43% had “Borderline NASH,” and 25% had NAFLD but not NASH. Total plasminogen activator
inhibitor 1 (PAI1) and activated PAI1 levels were higher in pediatric participants with Definite NASH and with lobular
inflammation. Interleukin-8 (IL-8) was higher in those with stage 3-4 fibrosis and lobular inflammation. Soluble IL-2
receptor alpha was higher in children with stage 3-4 fibrosis and portal inflammation. In multivariable analysis, PAI1 vari-
ables were discriminators of Borderline/Definite NASH, Definite NASH, lobular inflammation, and ballooning. IL-
8 increased with steatosis and fibrosis severity; soluble IL-2 receptor alpha increased with fibrosis severity and portal
inflammation. IL-7 decreased with portal inflammation and fibrosis severity. Conclusion: Plasma cytokines associated with
histology varied considerably among NASH features, suggesting promising avenues for investigation. More targeted analy-
sis is needed to identify the role of these markers in NAFLD and to evaluate their potential as noninvasive discriminators
of disease severity. (Hepatology Communications 2017;1:609–622)
Introduction
Nonalcoholic fatty liver disease (NAFLD) isthe most common pediatric liver disease inthe United States. A subset of children with
NAFLD have nonalcoholic steatohepatitis (NASH),
which can progress to cirrhosis(1) and increases the risk
for morbidities, including diabetes, cardiovascular dis-
ease, and hepatocellular carcinoma.(2,3) Routine imag-
ing and blood tests are helpful to identify children and
adolescents with NAFLD, but liver biopsy is currently
Abbreviations: AIC, Akaike information criterion; ALT, alanine aminotransferase; aPAI1, activated plasminogen activator inhibitor 1; AST, aspar-
tate aminotransferase; BMI, body mass index; CI, confidence interval; hpf, high-powered field; IGF-II, insulin-like growth factor 2; IL, interleukin;
MMP-9, matrix metallopeptidase 9; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NASH CRN, NASH Clinical
Research Network; OR, odds ratio; OSA, obstructive sleep apnea; PAI1, plasminogen activator inhibitor 1; sIL-1RI, soluble IL-1 receptor 1; TGF,
transforming growth factor; TNF, tumor necrosis factor; TONIC, treatment of nonalcoholic fatty liver disease in children; tPAI1, total plasminogen
activator inhibitor 1; VEGF, vascular endothelial growth factor.
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required for diagnosis of NASH and for staging
NASH severity.
Immune system pathways that drive hepatic steato-
sis, inflammation, apoptosis, and fibrosis in NASH are
insufficiently understood. In addition, diagnosing
NASH severity and histologic pattern requires a liver
biopsy, an invasive procedure that relies on a limited
liver sample. We lack reliable noninvasive markers for
inflammation severity, hepatocellular ballooning, fibro-
sis, and the age-specific pattern of NASH histology.
To address these two gaps, we have recently reported
on assocations between NASH histologic severity and
cytokine levels in adult NASH Clinical Research Net-
work (NASH CRN) participants.(4) NASH histologic
patterns stereotypically differ between children and
adults, although overlap is observed. This parallel
investigation of cytokine associations with histology in
pediatric NASH CRN participants provides novel
insight into differences and similarities. By examining
a panel of cytokines in a large pediatric cohort, we
provide direction for more targeted investigations of
promising biomarkers.
Children can have the “adult-type” zone 3 NASH,
with pericentral/sinusoidal fibrosis and primarily lobu-
lar inflammation, with or without ballooned hepato-
cytes. However, they can also have a “pediatric”
NASH, called zone 1 NASH, characterized by peri-
portal (i.e., zone 1) or panacinar steatosis, portal fibro-
sis, and primarily portal inflammation. It is not yet
clear whether zone 1 NASH is a precursor to or dis-
tinct entity from zone 3 NASH, nor how their natural
histories differ, although advanced fibrosis and cirrho-
sis can be an end stage for either.(5)
Previous studies of biomarkers for NASH in chil-
dren examined a limited number of biomarkers in
small cohorts.(6-14) Most studies did not evaluate
NASH histology, instead relying on surrogate markers
or imaging as a substitute for diagnosis.(8,11-14) Plas-
minogen activator inhibitor 1 (PAI1) has been associ-
ated with NAFLD in three studies in children(9,10,15)
as well as adult studies; but other markers, including
tumor necrosis factor alpha (TNF-a), interleukin (IL)-
6, IL-10, and resistin have been inconsistent predictors
of NAFLD in smaller cohorts of adults and children
(n 5 40-65).(7,9,10,16-18)
This study provides a unique examination of a set of
plasma biomarkers in a large cohort of children with
biopsy-proven NAFLD. Cytokines and other analytes
were chosen a priori as possible NASH predictors
based on their known role in steatosis, inflammation,
fibrosis, angiogenesis, or glucose metabolism. Our
aims were to gain insight into the cellular pathways
driving NASH and to refine the search for potential
noninvasive biomarkers of NASH severity and sub-
type. We also evaluated associations in children with
borderline zone 3 and borderline zone 1 NASH to
investigate whether processes driving NASH in these
two groups appear to be similar or distinct.
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Patients and Methods
STUDY DESIGN
This was a cross-sectional study using enrollment
data from pediatric participants in the NASH CRN, a
multicenter network sponsored by the National Insti-
tute of Diabetes, Digestive and Kidney Diseases since
2002.(19) Study participants were drawn from two
groups within the NASH CRN: (1) Treatment of
NAFLD in Children (TONIC) trial (ClinicalTrials.
gov Identifier:NCT00063635) and (2) NAFLD Data-
base study, an observational cohort. Both studies have
Institutional Review Board approval at all clinical centers
participating in the NASH CRN. Written permission
was obtained prior to participation from a parent/guard-
ian; written assent was obtained from children 8 years
old. NASH CRN Pediatric and Resource centers are
listed in the Acknowledgment section.
STUDY POPULATION
The NAFLD Database was an observational study
of participants 2 years and older with NAFLD. Eligi-
bility for the NAFLD Database study included having
either a histologic diagnosis of NAFLD or cryptogenic
cirrhosis with suspected NAFLD based on imaging
studies. The TONIC trial was a phase IIb, double-
masked, randomized, placebo-controlled trial of met-
formin or vitamin E versus placebo in children 8-17
years of age with NAFLD. Participants in TONIC
were required to have a baseline alanine aminotransfer-
ase (ALT) value of 60 U/L or greater and biopsy-
proven NAFLD.(20) Exclusion criteria for both studies
included no or restricted alcohol intake, other chronic
liver diseases, history of parenteral nutrition, bariatric
or hepatobiliary surgery, human immunodeficiency
virus infection, inborn errors of metabolism, or short-
bowel syndrome. Additional exclusion criteria for
TONIC included age less than 8 years, diagnosis of
diabetes, cirrhosis, use of drugs associated with
NAFLD, antidiabetic or anti-NAFLD drugs, meta-
bolic acidosis, and renal dysfunction. Enrollment
began in September 2004 for the NAFLD Database
and in August 2005 for TONIC.(21) Data collection
for this analysis was completed by April 2010. Both
studies have been described.(20,22) Participants from
both studies age 17 years and younger (total TONIC,
n 5 173; NAFLD Database, n 5 116) were eligible
for inclusion in the current study if they had a fasting
plasma sample available within 6 months of liver
biopsy reviewed by the central Pathology Committee
(TONIC, n 5 173; NAFLD Database, n 5 79) and
had at least two plasma aliquots available for analysis
(TONIC, n5 162; NAFLD Database, n5 73).
CLINICAL AND LABORATORY
ASSESSMENT
Demographic data and self-reported doctor-diag-
nosed comorbidities were obtained via structured inter-
view and questionnaires. Height, weight, and waist/
hip measurements were taken in duplicate while stand-
ing, wearing light clothing, and averaged for analyses.
Height and weight were measured without shoes to
the nearest 0.1 cm and 0.1 kg, respectively. Body mass
index (BMI) was calculated as weight (kg) divided by
height (m) squared. The BMI z-score was determined
according to age, sex, height, and weight based on data
from the Centers for Disease Control and Prevention
2000 reference population.(23)
Fasting whole blood samples were obtained via veni-
puncture after an overnight fast of 8 hours or more and
processed for plasma and serum within 2 hours. Labora-
tory assays were performed at individual clinical centers
and included platelet count (109 cells/L), bilirubin (mg/
dL), ALT (U/L), aspartate aminotransferase (AST; U/
L), triglycerides and cholesterol fractions (mg/dL), glu-
cose (mg/dL), and insulin (mU/mL). Homeostasis
model assessment of insulin resistance was calculated
from fasting insulin and glucose values.(24)
HISTOLOGIC EVALUATION
Biopsy specimens were evaluated centrally by the
NASH CRN Pathology Committee according to the
validated histologic scoring system by Kleiner et al.(25)
for steatosis (grade 0 [<5% macrovesicular fat], grade
1 [5%-33%], grade 2 [34%-66%], and grade 3
[>66%]), portal inflammation (0-2 [none, mild, more
than mild]), lobular inflammation (0-3 [none, <2 foci
per high-powered field [hpf], 2-4 foci, >4 foci per
203 field]), ballooning degeneration (0-2 [none, few,
many]), and fibrosis (stage 0, stage 1a [mild perisinu-
soidal], stage 1b [moderate perisinusoidal], stage 1c
[portal/periportal fibrosis only], stage 2 [zone 3 and
periportal], stage 3 [bridging fibrosis], and stage 4
[cirrhosis]).
A diagnostic categorization was determined for each
case: NAFLD, Not NASH, Borderline Zone 3, Bor-
derline Zone 1, or Definite NASH.(22,26) Borderline
Zone 1 NASH presents mainly in children and is
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characterized by periportal fibrosis with steatosis
involving zone 1 and minimal or no zone 3 injury.(26)
Definite NASH unequivocally fulfilled previously
defined criteria for steatohepatitis,(25) whereas the cate-
gory NAFLD, Not NASH encompasses cases of
NAFLD in which diagnostic NASH features are
absent.
PLASMA BIOMARKER
MULTIPLEX ASSAY
Thirty-two plasma biomarkers were chosen a priori
as possible predictors of NASH or its components
(steatosis, inflammation, fibrosis), energy homeostasis,
angiogenesis, or metabolism of lipids, glucose, and
insulin. Biomarkers were measured from an enrollment
sample for all children, which was prior to beginning
medications for those in the TONIC trial. Blood sam-
ples were obtained by venipuncture and plasma col-
lected by centrifugation and stored at –808C. Plasma
samples were measured in duplicate using the Luminex
Multiplex platform (Millipore, St. Louis, MO) and
processed according to standard protocol. Detection by
Luminex is comparable to that with enzyme-linked
immunosorbent assay, but the required input plasma
volume is drastically reduced. Quality control proce-
dures were employed to ensure high-quality data for
downstream analyses.
The coefficient of variation for plasma biomarkers
was required to be less than 20%, a criterion met for all
biomarkers included in this analysis (Supporting Table
S1). Biomarkers available in less than 90% of the
sample were excluded (glucagon-like peptide 1, soluble
vascular endothelial growth factor receptor 1, IL-1a,
IL-12/40 kDa subunit, IL-13, transforming growth
factor beta 3 [TGF-b3]).
STATISTICAL ANALYSIS
This analysis considered clinical and plasma bio-
marker predictors of histologic outcomes. Histologic
outcomes were collapsed into binary categories as fol-
lows: NASH diagnosis (Not/Borderline NASH versus
Definite NASH, Not versus Definite NASH), steato-
sis severity (steatosis 33% versus steatosis >33%),
inflammatory pattern and severity (lobular, <2 foci per
hpf versus 2 per hpf; portal, none/mild versus more
than mild), hepatocellular ballooning (none versus few/
many), and fibrosis severity. For fibrosis severity, two
categorizations were considered: (1) no fibrosis (stage
0) versus any fibrosis (stage 1-4) and (2) no/minimal
fibrosis (stage 0-2) versus significant fibrosis (stage
3-4).
Descriptive statistics and frequency distributions
were generated on the sample demographic and clinical
characteristics and plasma biomarker measurements.
The Student t test accounting for unequal variances
(Tables 1 and 2; Supporting Tables S2-S4) and logistic
regression (Tables 3 and 4) were used for bivariate
analysis of associations between continuous clinical
characteristics or biomarker discriminators and histo-
logic outcomes, and Pearson’s chi-square test was used
for categorical clinical characteristics (Table 1). All
odds ratios (ORs) for cytokines in univariable and
TABLE 1. CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF THE COHORT BY NASH DIAGNOSIS
Total
(n 5 235)
Not NASH
(n 5 62)
Borderline Zone 1
NASH (n 5 53)
Borderline Zone 3
NASH (n 5 47)
Definite NASH
(n 5 73)
% % % % %
Female 22.4 26.7 13.2 26.1 23.3
Race
Hispanic 59.5 61.2 64.2 58.7 54.7
White, non-Hispanic 33.6 31.2 32.1 32.6 36.9
Black, non-Hispanic 1.7 1.7 0 4.4 1.3
Other, non-Hispanic 5.2 5.0 3.8 4.4 6.8
Mean 6 SD Mean 6 SD Mean 6 SD Mean 6 SD Mean 6 SD
Age at biopsy (years) 13.1 6 2.6 13.6 6 2.9 11.8 6 2.0 13.6 6 2.8 13.5 6 2.3
BMI z-score 2.3 6 0.4 2.3 6 0.7 2.3 6 0.3 2.3 6 0.4 2.3 6 0.3
ALT (U/L) 107.5 6 74.6 76.4 6 42.9 104.6 6 53.4 97.5 6 61.9 143.5 6 99.7
AST (U/L) 62.7 6 40.2 45.8 6 25.3 61.3 6 31.7 54.1 6 26.6 83.6 6 52.9
Total bilirubin (mg/dL) 0.7 6 0.3 0.7 6 0.4 0.7 6 0.3 0.7 6 0.3 0.6 6 0.3
Triglycerides (mg/dL) 147.7 6 94.6 126.9 6 59.0 137.3 6 109.7 151.0 6 108.5 170.4 6 94.5
HDL cholesterol (mg/dL) 37.9 6 9 37.3 6 7.7 41.6 6 10.8 38.0 6 10.4 35.6 6 6.8
HOMA-IR 8.3 6 10.7 7.5 6 9.4 6.9 6 6.1 7.2 6 5.6 10.5 6 15.1
Abbreviations: HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance.
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multivariable analysis are reported per 0.5 SD change
in the cytokine based on SDs for the total group as
reported in Table 2. Significance using the Benjamini-
Hochberg correction with a false discovery rate of 10%
also provided for univariate logistic regression of cyto-
kine changes with outcomes.(27)
Given the number of predictors considered and the
exploratory aim of this analysis, predictors were chosen
for the final multivariable models to minimize the
Akaike information criterion (AIC) (Table 5). AIC
minimization allows choice of the model that best fits
the data with penalization for the number of predictors
included; it is an empiric method for optimizing model
fit without overfitting. The AIC statistic is calculated
using a model’s log-likelihood, the number of parame-
ters included in the model, and the sample size. AIC
for candidate models are compared, and the model
with the lowest AIC is retained. AIC comparisons are
automated, as described below, such that all variable
combinations can be tested. The order of variable
inclusion/exclusion does not impact results, thus avoid-
ing incorrect selection that can be caused by stepwise
selection methods in data sets with many predictors.
First, all cytokines were competed in a logistic
regression model. The model with the lowest AIC,
i.e., the best data fit with penalization for the number
of predictors included, was retained for each outcome.
That limited groups of cytokines competed in a second
logistic regression model with clinical predictors cho-
sen a priori for their association with NASH diagnosis
and severity (age, sex, BMI z-score, AST, ALT, trigly-
cerides, high-density lipoprotein, and homeostasis
model assessment of insulin resistance). Cytokine and
clinical predictors retained in the AIC-minimized
model were re-entered into a final logistic regression to
obtain the results reported in Table 5. Thus, inclusion
in this final model was based on AIC values, not on P
values. Sensitivity analysis was done excluding those
children with Borderline Zone 1 NASH.
For multivariable models, missing values for cyto-
kine and clinical data were imputed using a multiple
imputations technique with progressive mean match-
ing and iterative chained equations. To allow for auto-
mated AIC minimization, the mean of 20 imputed
values was retained and used for predictor selection in
the same process described above. All statistical
TABLE 2. PLASMA BIOMARKER LEVELS AND NASH DIAGNOSIS
Total
Not/Borderline NASH
(n 5 162)
Definite NASH
(n 5 73)
n Mean 6 SD Mean 6 SD Mean 6 SD P
Adiponectin (lg/mL) 233 13.1 6 7.48 13.20 6 7.26 13.00 6 7.98 0.92
aPAI1 (ng/mL) 233 54.97 6 43.96 50.46 6 45.09 64.87 6 39.93 0.02
FGF2 (pg/mL) 232 98.6 6 141.3 93.8 6 146 109.1 6 130.9 0.42
Fibrinogen (mg/mL) 234 4.39 6 2.11 4.44 6 1.69 4.31 6 2.84 0.72
Haptoglobin (mg/mL) 235 2.47 6 1.27 2.48 6 1.27 2.44 6 1.28 0.81
IFN-c (pg/mL) 218 8.7 6 21.3 8.3 6 21.3 9.6 6 21.5 0.69
IGF-II (mg/mL) 234 1.83 6 0.99 1.79 6 0.99 1.89 6 1.02 0.48
IL-1b (pg/mL) 215 0.5 6 0.8 0.5 6 0.8 0.6 6 0.6 0.78
IL-2 (pg/mL) 226 3.7 6 8.8 3.6 6 9.8 4.0 6 5.8 0.65
IL-4 (pg/mL) 226 24.8 6 31.9 24.5 6 32.5 25.4 6 30.7 0.84
IL-5 (pg/mL) 230 1.0 6 1.8 0.9 6 1.9 1.1 6 1.6 0.52
IL-6 (pg/mL) 235 15.2 6 91.1 16.7 6 108.6 12.0 6 24.0 0.6
IL-7 (pg/mL) 226 5.0 6 6.4 5.2 6 7.4 4.7 6 3.5 0.47
IL-8 (pg/mL) 235 3.1 6 2.0 2.9 6 2.2 3.4 6 1.5 0.07
IL-10 (pg/mL) 234 24.9 6 99.4 26.1 6 118.2 22.2 6 27.5 0.69
MCP-1 (pg/mL) 235 246.5 6 100.6 246.9 6 105.3 245.7 6 90 0.93
MMP-9 (ng/mL) 235 63.9 6 33.3 64.1 6 35.7 63.4 6 27.6 0.88
Resistin (ng/mL) 234 14.89 6 6.32 14.91 6 6.49 14.87 6 5.97 0.97
sFasL (pg/mL) 227 107.6 6 71.4 110.2 6 78.8 102.1 6 51.1 0.36
sIL-1RI (pg/mL) 235 33.8 6 23.0 32.2 6 23.8 37.2 6 32.4 0.11
sIL-2Ra (ng/mL) 235 0.79 6 0.36 0.79 6 0.34 0.79 6 0.41 0.91
sIL-6R (ng/mL) 235 21.24 6 5.39 21.33 6 5.37 21.04 6 5.49 0.71
TGF-b1 (ng/mL) 235 6.86 6 7.61 7.11 6 8.63 6.28 6 4.59 0.34
TGF-b2 (pg/mL) 223 359.6 6 343.1 377.9 6 401.1 321.2 6 161.2 0.13
TNF-a (pg/mL) 235 8.4 6 8.8 7.6 6 5.0 10.1 6 13.9 0.13
tPAI1 (ng/mL) 235 45.8 6 24.8 43.2 6 24.3 51.4 6 25.1 0.02
VEGF (pg/mL) 235 551.3 6 1083.4 473.9 6 981.7 723 6 1271.3 0.14
Abbreviations: FGF2, fibroblast growth factor 2; IFN-c, interferon gamma; MCP-1, monocyte chemoattractant protein-1; sFasL, sol-
uble Fas ligand.
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analyses were performed using STATA (StataCorp
LP, College Station, TX). Multivariable model results
without multiple imputations are reported in Support-
ing Table S5.
Results
CHARACTERISTICS OF THE
STUDY POPULATION
Included in this study were 235 subjects, 73 from
the NAFLD Database and 162 from the TONIC trial.
Children from the NAFLD Database and TONIC
were grouped together because there were no differ-
ences in their participation or care prior to collection of
baseline data. Of the 235 children and adolescents
included, 4 had no steatosis, 58 were classified as
NAFLD, Not NASH (25%), and 73 (31%) were cate-
gorized as Definite NASH. The remaining 100 had
Borderline NASH, with 47 of those (20% of total)
having a Borderline Zone 3 NASH pattern and 53
(23% of total) a Borderline Zone 1 pattern. Clinical
characteristics associated with NASH are noted in
Table 1 and have been described in additional detail in
previous NASH CRN analyses.(20,22)
Children classified as Borderline Zone 1 NASH
were younger than those with Borderline/Definite
Zone 3 NASH (11.8 6 2.0 years versus 13.5 6 2.5,
P < 0.0005), but there were no differences by sex,
race, ethnicity, BMI z-score, transaminases, glucose,
or insulin.
PLASMA BIOMARKERS
ASSOCIATED WITH NASH
DIAGNOSIS
In bivariate analysis, participants with Definite
NASH had significantly higher levels of activated
TABLE 3. UNADJUSTED OR (95% CI) FOR CHANGE IN CYTOKINE LEVEL BY 0.5 SD BY HISTOLOGIC
OUTCOME
Definite NASH
(vs. Not/Borderline)
Any Fibrosis
(stage 1-4)
Significant Fibrosis
(stage 3-4)
Steatosis
(>33%)
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Adiponectin (lg/mL) 0.99 0.86-1.14 0.91 0.80-1.04 1.01 0.84-1.21 0.95 0.82-1.09
aPAI1 (ng/mL) 1.18* 1.01-1.38 1.09 0.93-1.28 1.15 0.99-1.35 1.13 0.95-1.35
FGF-2 (pg/mL) 1.05 0.92-1.20 0.92 0.80-1.06 1.05 0.91-1.22 0.97 0.85-1.10
Fibrinogen (mg/mL) 0.97 0.84-1.12 1.03 0.89-1.19 1.09 0.94-1.27 0.92 0.80-1.05
Haptoglobin (mg/mL) 0.98 0.82-1.18 0.95 0.83-1.10 0.98 0.82-1.18 0.92 0.80-1.06
IFN-c (pg/mL) 1.03 0.90-1.18 0.99 0.86-1.13 0.86 0.57-1.29 0.94 0.82-1.07
IGF-II (mg/mL) 1.05 0.92-1.21 0.98 0.85-1.12 0.90 0.73-1.09 1.18* 1.00-1.38
IL-1b (pg/mL) 1.02 0.88-1.18 0.96 0.83-1.11 0.87 0.65-1.17 0.90 0.77-1.04
IL-2 (pg/mL) 1.03 0.90-1.17 0.90 0.76-1.05 0.77 0.44-1.35 0.93 0.81-1.07
IL-4 (pg/mL) 1.01 0.88-1.16 1.02 0.88-1.18 0.89 0.70-1.15 0.98 0.85-1.13
IL-5 (pg/mL) 1.04 0.91-1.19 0.98 0.86-1.12 0.92 0.69-1.22 1.03 0.87-1.20
IL-6 (pg/mL) 0.97 0.81-1.16 0.89 0.69-1.15 0.98 0.78-1.23 1.05 0.84-1.31
IL-7 (pg/mL) 0.96 0.82-1.12 0.89 0.77-1.03 0.77 0.55-1.09 0.98 0.85-1.12
IL-8 (pg/mL) 1.11 0.97-1.27 1.13 0.97-1.33 1.20* 1.03-1.39 1.12 0.95-1.32
IL-10 (pg/mL) 0.98 0.83-1.15 0.93 0.79-1.09 1.01 0.86-1.19 1.06 0.83-1.35
MCP-1 (pg/mL) 0.99 0.87-1.14 1.01 0.88-1.16 1.13 0.97-1.32 1.03 0.89-1.19
MMP-9 (ng/mL) 0.99 0.86-1.14 1.13 0.96-1.32 0.98 0.82-1.18 0.88 0.77-1.01
Resistin (ng/mL) 1.00 0.87-1.15 1.08 0.93-1.25 1.16 0.99-1.36 1.08 0.93-1.26
sFasL (pg/mL) 0.94 0.81-1.09 1.02 0.88-1.17 0.98 0.81-1.18 1.14 0.96-1.36
sIL-1RI (pg/mL) 1.11 0.97-1.27 1.00 0.87-1.14 1.05 0.89-1.24 1.11 0.93-1.32
sIL-2Ra (ng/mL) 0.99 0.86-1.14 1.13 0.97-1.31 1.39† 1.18-1.64 0.98 0.85-1.12
sIL-6R (ng/mL) 0.97 0.85-1.12 0.99 0.86-1.13 1.20 0.99-1.44 1.00 0.86-1.15
TGF-b1 (ng/mL) 0.94 0.81-1.10 1.05 0.91-1.21 0.89 0.70-1.12 1.00 0.87-1.16
TGF-b2 (pg/mL) 0.90 0.75-1.08 1.04 0.89-1.22 0.96 0.77-1.18 0.99 0.85-1.14
TNF-a (pg/mL) 1.18 0.97-1.44 1.10 0.89-1.326 0.87 0.62-1.23 1.06 0.88-1.29
tPAI1 (ng/mL) 1.17* 1.02-1.34 1.07 0.92-1.23 1.09 0.92-1.29 1.08 0.93-1.25
VEGF (pg/mL) 1.11 0.97-1.27 1.04 0.89-1.20 1.02 0.86-1.21 1.01 0.87-1.16
*P  0.05 before correction for multiple comparisons.
†P  0.05 before correction and significance retained with Benjamini-Hochberg correction.
Abbreviations: FGF2, fibroblast growth factor 2; IFN-c, interferon gamma; MCP-1, monocyte chemoattractant protein-1; sFasL, sol-
uble Fas ligand.
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PAI1 (aPAI1) and total PAI1 (tPAI1) than those with
Not/Borderline NASH (Tables 2 and 3). In multivari-
able regression models, Definite NASH was associated
with higher TNF-a levels as well as clinical predictors
(Table 5).(22)
Comparison was also made between children with
Definite NASH (n 5 73) and those with Not NASH
(n 5 62), excluding those with Borderline NASH.
Those with Definite NASH had significantly higher
tPAI1 (51.4 6 25.1 ng/mL versus 38.8 6 21.9 ng/
mL; P 5 0.002), aPAI1 (64.8 6 35.9 versus 45.8 6
35.9 ng/mL; P 5 0.004), and IL-8 (3.37 6 1.54 pg/
mL versus 2.46 6 1.89 pg/mL; P 5 0.003) than those
with Not NASH.
In sensitivity analysis excluding participants with
Borderline Zone 1 NASH, children with Definite
Zone 3 NASH (n 5 108) had higher aPAI1 (64.9 6
39.9 versus 44.8 6 31.2; P 5 0.0004), tPAI1 (51.4 6
21.0 versus 40.7 6 25.1; P 5 0.003), IL-8 (3.38 6
1.54 versus 2.706 1.98; P5 0.01), and vascular endo-
thelial growth factor (VEGF; 723.0 6 1271.3 versus
404.2 6 609.9; P 5 0.05) levels than those with Not/
Borderline Zone 3 NASH (n 5 73). In multivariable
analysis excluding those with Borderline Zone 1
NASH, significant discriminators of Definite NASH
versus Not/Borderline Zone 3 NASH were aPAI1
(OR, 1.25 per 0.5 SD increase; 95% confidence inter-
val [CI], 1.01-1.56; P 5 0.04), AST (OR, 1.65 per 20
IU/L increase; 95% CI, 1.30-2.11; P <0.005), and tri-
glycerides (OR, 1.06 per 20 mg/dL increase; 95% CI,
0.98-1.14; P 5 0.14).
Soluble IL-1 receptor 1 (sIL-1RI) was higher in
children with Borderline/Definite Zone 3 NASH
(37.06 6 25.39 pg/mL) than those with Borderline
Zone 1 NASH (30.29 6 16.37 pg/mL; P 5 0.04).
There were no other significant differences in analyte
levels between participants with Borderline/Definite
Zone 3 and Zone 1 NASH (data not shown).
TABLE 4. UNADJUSTED OR (95% CI) FOR CHANGE IN CYTOKINE LEVEL BY 0.5 SD BY HISTOLOGIC
OUTCOME
Lobular Inflammation
(2 foci per hpf)
Portal Inflammation
(mild/more than mild) Hepatocellular Ballooning
OR 95% CI OR 95% CI OR 95% CI
Adiponectin (lg/mL) 1.03 0.91-1.17 1.04 0.82-1.30 1.02 0.90-1.17
aPAI1 (ng/mL) 1.29† 1.09-1.52 1.17 0.86-1.59 1.14 0.98-1.33
FGF-2 (pg/mL) 1.26* 1.01-1.59 1.15 0.76-1.72 1.04 0.91-1.20
Fibrinogen (mg/mL) 0.93 0.81-1.07 1.02 0.81-1.30 0.96 0.84-1.10
Haptoglobin (mg/mL) 1.00 0.88-1.14 0.80* 0.65-0.98 0.99 0.87-1.13
IFN-c (pg/mL) 1.06 0.92-1.22 1.11 0.73-1.68 0.99 0.87-1.13
IGF-II (mg/mL) 0.99 0.87-1.13 0.98 0.79-1.22 1.01 0.89-1.15
IL-1b (pg/mL) 1.06 0.92-1.23 1.10 0.79-1.53 1.01 0.88-1.16
IL-2 (pg/mL) 1.00 0.88-1.14 0.99 0.80-1.22 1.10 0.92-1.31
IL-4 (pg/mL) 1.06 0.93-1.21 0.97 0.79-1.19 0.97 0.85-1.11
IL-5 (pg/mL) 0.98 0.86-1.12 1.21 0.72-2.05 0.98 0.85-1.11
IL-6 (pg/mL) 1.25 0.66-2.37 1.46 0.30-7.06 1.21 0.67-2.17
IL-7 (pg/mL) 0.96 0.84-1.10 0.95 0.80-1.14 1.01 0.89-1.15
IL-8 (pg/mL) 1.14* 1.00-1.31 1.06 0.83-1.36 1.06 0.93-1.20
IL-10 (pg/mL) 0.93 0.76-1.14 2.47 0.35-17.54 0.94 0.79-1.12
MCP-1 (pg/mL) 1.12 0.98-1.29 0.96 0.79-1.18 1.02 0.90-1.16
MMP-9 (ng/mL) 1.11 0.97-1.27 1.48* 1.02-2.14 1.09 0.95-1.24
Resistin (ng/mL) 1.14 0.99-1.30 0.96 0.78-1.18 0.94 0.83-1.07
sFasL (pg/mL) 0.95 0.83-1.08 1.18 0.88-1.58 0.91 0.79-1.04
sIL-1RI (pg/mL) 0.95 0.83-1.08 1.06 0.82-1.38 1.13 0.98-1.30
sIL-2Ra (ng/mL) 1.03 0.90-1.17 1.48* 1.07-2.06 0.99 0.87-1.12
sIL-6R (ng/mL) 1.17* 1.02-1.33 1.09 0.88-1.37 0.98 0.86-1.11
TGF-b1 (ng/mL) 0.86 0.74-1.00 0.99 0.80-1.23 0.90 0.79-1.04
TGF-b2 (pg/mL) 0.84 0.70-1.00 0.98 0.80-1.21 0.90 0.78-1.05
TNF-a (pg/mL) 0.99 0.87-1.12 1.21 0.75-1.94 1.12 0.93-1.35
tPAI1 (ng/mL) 1.22† 1.06-1.40 1.12 0.87-1.44 1.18* 1.03-1.35
VEGF (pg/mL) 1.11 0.96-1.28 1.43 0.78-2.60 1.14 0.97-1.33
*P  0.05 before correction for multiple comparisons.
†P  0.05 before correction and significance retained with Benjamini-Hochberg correction.
Abbreviations: FGF2, fibroblast growth factor 2; IFN-c, interferon gamma; MCP-1, monocyte chemoattractant protein-1; sFasL, sol-
uble Fas ligand.
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TABLE 5. PREDICTORS ASSOCIATED WITH NASH AND HISTOLOGIC COMPONENTS IN MULTIVARIABLE
ANALYSIS*
NAFLD Group Comparison Predictor (per unit change†) Odds Ratio 95% CI P
Definite NASH (vs.
Borderline/Not NASH)
Age (1 year) 1.12 0.99-1.26 0.07
AST (20 U/L) 1.56 1.29-1.88 <0.001
HDL cholesterol (5 mg/dL) 0.78 0.64-0.95 0.01
TNF-a (4.4 pg/mL) 1.19 0.97-1.46 0.10
v2 5 42.46, P < 0.0005, n 5 230
Definite NASH
(vs. Not NASH) AST (20 U/L) 2.18 1.49-3.19 <0.0001
Triglycerides (20 mg/dL) 1.15 1.02-1.28 0.02
VEGF (514.5 pg/mL) 1.30 0.98-1.71 0.07
v2 5 45.58, P < 0.0005, n 5 134
Steatosis >33% Male 1.81 0.88-3.78 0.11
Age (1 year) 0.87 0.76-0.99 0.03
BMI z-score (1) 1.96 0.83-4.64 0.13
ALT (20 U/L) 1.09 0.99-1.22 0.09
IGF-II (1 pg/mL) 1.28 1.06-1.55 0.01
MMP-9 (16.5 ng/mL) 0.84 0.72-0.98 0.02
Resistin (3.15 ng/mL) 1.13 0.95-1.33 0.17
sFasL (35.5 pg/mL) 1.09 0.92-1.28 0.33
v2 5 25.95, P 5 0.001, n 5 229
Stage 1-4 fibrosis AST (20 U/L) 1.30 1.05-1.61 0.02
IL-5 (0.9 pg/mL) 1.28 0.92-1.78 0.14
IL-7 (3.2 pg/mL) 0.62 0.46-0.84 0.002
IL-8 (1 pg/mL) 1.23 0.95-1.59 0.11
MMP-9 (16.5 ng/mL) 1.20 1.01-1.41 0.03
v2 5 26.14, P 5 0.0001, n 5 233
Stage 3-4 fibrosis AST (20 IU/mL) 1.40 1.13-1.74 0.002
IL-4 (16 pg/mL) 0.63 0.36-1.09 0.10
IL-7 (3.2 pg/mL) 0.32 0.15-0.66 0.002
IL-8 (1 pg/mL) 1.77 1.31-2.38 <0.0005
IL-10 (50 pg/mL) 2.20 1.21-3.98 0.01
sIL-2ra (0.18 ng/mL) 1.48 1.20-1.84 <0.0005
v2 5 60.45, P < 0.0005, n 5 234
Mild/more than mild portal inflammation Haptoglobin (0.65 mg/mL) 0.80 0.65-1.00 0.05
sIL-2ra (0.18 ng/mL) 1.45 1.04-2.02 0.03
MMP-9 (16.5 ng/mL) 1.31 0.93-1.84 0.12
v2 5 14.94, P 5 0.002, n 5 235
Lobular inflammation
(2 foci per hpf)
Male 0.47 0.22-0.98 0.04
AST (per 20 U/L) 1.35 0.89-2.05 0.16
ALT (per 20 U/L) 1.18 0.95-1.48 0.14
HDL cholesterol (per 5 mg/dL) 0.86 0.72-1.04 0.13
Resistin (per 3.15 ng/mL) 1.20 1.02-1.42 0.03
sIL-2ra (per 0.18 ng/mL) 0.85 0.72-1.00 0.06
sIL-6R (per 2.7 ng/mL) 1.26 1.07-1.48 0.005
TGF-b2 (per 171.5 pg/mL) 0.62 0.47-0.82 0.001
tPAI1 (per 12.4 ng/mL) 1.37 1.13-1.65 0.001
v2 5 71.67, P <0.0005, n 5 227
Hepatocellular ballooning AST (per 20 U/L) 1.26 1.06-1.50 0.008
Triglycerides (per 20 mg/dL) 1.09 1.02-1.16 0.02
TGF-b1 (per 3.8 pg/mL) 0.78 0.65-0.94 0.008
tPAI1 (per 12.4 ng/mL) 1.23 1.04-1.45 0.02
v2 5 30.10, P <0.0005, n 5 233
*Models include imputation of missing cytokine and clinical values by progressive mean matching and chained iterative equations. See
Supporting Table S5 for multivariate models without imputed missing values.
†Per unit change represents 0.5 SD change for cytokine biomarkers and clinically significant change for clinical predictors.
Abbreviations: HDL, high-density lipoprotein; sFasL, soluble Fas ligand
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PLASMA BIOMARKERS
ASSOCIATED WITH
STEATOSIS GRADE
Forty percent of participants had >66% steatosis
(grade 3), 32% had 34%-66% (grade 2), 26% had 5%-
33% (grade 1), and 2% had <5% steatosis (grade 0).
Participants with moderate to severe steatosis (grade 2-
3) had higher levels of insulin-like growth factor 2
(IGF-II; P 5 0.03, Table 3; Supporting Table S3). In
multivariable modeling, steatosis >33% was associated
with higher IGF-II, resistin, and soluble Fas ligand
levels and lower matrix metallopeptidase 9 (MMP-9)
levels (Table 4). When subjects with Borderline Zone
1 NASH were excluded for sensitivity analysis, IGF-II
remained significantly associated with moderate-severe
steatosis (OR, 1.85; 95% CI, 1.16-2.96; P 5 0.01);
IL-1b was also retained in this model (OR, 0.69; 95%
CI, 0.41-1.18; P 5 0.18) with ALT, BMI z-score,
and age.
PLASMA BIOMARKERS
ASSOCIATED WITH
FIBROSIS STAGE
Thirty-two percent of participants had no fibrosis
on liver biopsy, 38% had stage 1 (perisinusoidal or
periportal only), 15% had stage 2, 14% stage 3, and 1%
stage 4 fibrosis. None of the biomarker distributions
were significantly different between those with no
fibrosis and those with stage 1-4 fibrosis (Table 3).
However, IL-8 and sIL-2Ra were significantly higher
in those who had stage 3-4 fibrosis compared to stage
0-2, and the latter retained statistical significance after
correction for multiple comparisons (Table 3).
In multivariable analysis, IL-7 levels were lower in
participants that had any fibrosis (versus none) and
stage 3-4 fibrosis (versus 0-1) (Table 4). Stage 3-4
fibrosis was also associated with lower IL-4 and higher
IL-8, IL-10, and sIL-2Ra (Table 4).
Compared to children with fibrosis in a zone 1 pat-
tern (periportal only), children with any fibrosis in an
adult NASH pattern had higher levels of IL-5 (1.12 6
1.65 versus 0.60 6 0.45, P 5 0.004), IL-10 (23.41 6
35.79 versus 14.80 6 15.00, P 5 0.04), and IL-1b
(0.58 6 0.62 versus 0.41 6 0.40, P 5 0.05) with no
significant differences in other cytokine levels between
the two groups (data not shown).
When participants with Zone 1 NASH fibrosis
(periportal only) were excluded, those with any fibrosis
in an adult NASH pattern (stage 1a, 1b, or 2-4; n 5
98) had higher IL-8 levels (3.41 6 2.25 pg/mL) than
those with no fibrosis (2.77 6 1.96 pg/mL; P 5 0.05,
n 5 75). There were no statistically significant differ-
ences in other biomarker levels between those with
adult NASH pattern fibrosis and those with no fibro-
sis. Those with significant fibrosis (stage 3-4; n 5 138)
had higher IL-8 (3.87 6 3.05 pg/mL versus 2.95 6
1.83 pg/mL in stage 0-2 fibrosis; n 5 35), sIL-2ra
(1.04 6 0.07 ng/mL versus 0.72 6 0.03 ng/mL), and
sIL-6R (22.83 6 4.74 ng/mL versus 20.93 6 5.22 ng/
mL) levels as well as lower IL-7 levels (3.64 6 3.91
pg/mL versus 5.52 6 7.40 pg/mL; P5 0.05).
In multivariable modeling excluding those with
Zone 1 NASH fibrosis (periportal only), any fibrosis
(stage 1-4) in an adult NASH pattern was associated
with increasing IL-5 (OR, 1.80 per 0.9 pg/mL
increase; 95% CI, 1.16-2.79; P5 0.01) and IL-8 levels
(OR, 1.41 per 1 pg/mL increase; 95% CI, 1.06-1.87;
P 5 0.02) as well as decreasing IL-7 (OR, 0.46 per 3.2
pg/mL increase; 95% CI, 0.30-0.72; P 5 0.001) and
increasing AST (OR, 1.39 per 20 IU/L increase; 95%
CI, 1.09-1.78; P 5 0.008). In the same group, fibrosis
stage 3-4 (versus 0-2) remained associated with dec-
reasing IL-7 and increasing AST as well as increasing
sIL-2Ra (OR, 1.56 per 0.18 ng/mL increase; 95% CI,
1.22-1.98; P < 0.0005) and IL-10 (OR, 2.77 per 50 /
mL increase; 95% CI, 1.27-6.04; P 5 0.01).
PLASMA BIOMARKERS
ASSOCIATED WITH
INFLAMMATION AND
HEPATOCELLULAR
BALLOONING
Lobular inflammation was seen in <2 foci per 203
field in 53% of participants, 2-4 foci in 42%, and more
than 4 foci in 5% (n 5 235). Compared to participants
with <2 foci of lobular inflammation, those with 2
foci had higher levels of aPAI1 and fibroblast growth
factor 2 that remained significant after correction for
multiple comparisons. They had higher tPAI1, IL-8,
and sIL-6R and lower levels of TGF-b1 and TGF-b2
before correction (Table 4). In multivariable modeling,
lobular inflammation was significantly associated with
higher resistin, sIL-6R, and tPAI1 levels and lower
TGF-b2 and sIL-2Ra levels (Table 4).
Chronic portal inflammation was absent in 9% of
children, mild in 81%, and more than mild in 10%.
Compared to those with no portal inflammation, those
with mild or more than mild portal inflammation had
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higher levels of MMP-9 and sIL-2Ra and lower levels
of haptoglobin (Table 5; Supporting Table S4). In
multivariable models, portal inflammation was associ-
ated with higher levels of MMP-9 and sIL-2Ra and
lower levels of haptoglobin (Table 4).
Hepatocyte ballooning was seen in 49% of partici-
pants. Those with ballooning had higher levels of
tPAI1 with no significant differences in other bio-
markers (Table 5; Supporting Table S3). The associa-
tion of ballooning with higher tPAI1, as well as lower
TGF-b1, was significant in multivariable analysis
(Table 4).
In the sample excluding those with Borderline Zone
1 NASH, participants with ballooning had higher lev-
els of tPAI1 (49.3 6 24.7 versus 40.0 6 20.4; P 5
0.006), aPAI1 (59.4 6 37.9 versus 45.2 6 32.8; P 5
0.007), sIL-1RI (38.1 6 27.5 versus 30.9 6 20.0; P 5
0.04), IL-8 (3.22 6 1.63 versus 2.68 6 2.03; P 5
0.05), and VEGF (667.8 6 1148.1 versus 373.7 6
593.1; P 5 0.03). Only 3% of pediatric participants
had Mallory bodies on baseline liver biopsy.
Discussion
This is the first report of an array of plasma bio-
markers related to metabolism, inflammation, and
fibrosis measured simultaneously with liver biopsy in
children and adolescents with NAFLD. The NASH
CRN cohort offers a unique opportunity to character-
ize differences in plasma biomarker levels by histologic
pattern and severity. Given the significant number of
cytokines evaluated, our aim was to identify promising
targets for future research.
In multivariable models, clinical characteristics, such
as sex, age, and AST, were associated most consistently
with overall NASH diagnosis and particular histologic
components. In addition, several analytes emerged
repeatedly in bivariate and multivariable analyses as sig-
nificantly associated with NASH histologic compo-
nents. These patterns provide targets for future research
into the inflammatory, fibrotic, and other pathways that
drive NAFLD development and progression.
One of the most consistent findings was the associa-
tion between NASH features and tPAI1 and aPAI1. In
bivariate analysis, increased tPAI1 and aPAI1 were asso-
ciated with Definite NASH and lobular inflammation.
In multivariable analysis, tPAI1 was associated with lobu-
lar inflammation and hepatocellular ballooning.
In the parallel analysis of cytokines in the adult
NASH CRN cohort, aPAI1 was the only cytokine
that discriminated between Definite NASH and Bor-
derline/Not NASH.(4) This association between PAI1
levels and NAFLD has been reported in other cohorts
of adults with NASH.(28,29) PAI1 has primarily been
studied for its role in atherosclerosis and thrombotic
disease.(30) It is not clear if PAI1 is itself mediating
inflammation and damage in the NASH liver or if
NASH inflammation induces PAI1 release, which
then contributes to systemic cardiovascular disease.(29)
The mechanisms are deserving of further investigation
as NAFLD is emerging as a significant risk factor for
cardiovascular events in adults, with severity of liver
disease correlating with cardiovascular event risk.(31)
PAI1 has also been reported as a predictor of NASH
and NAFLD activity score in obese children(9) and as
a predictor of steatosis severity in another cohort.(15)
The investigators hypothesized that PAI1 might be
involved in NASH hepatic inflammation; indeed
tPAI1 retained significance as a predictor in multivari-
able modeling of lobular inflammation and aPAI1 of
portal inflammation in our cohort.
Interestingly, PAI1 levels are also increased in
patients with obstructive sleep apnea (OSA).(32) In
children with NAFLD, OSA has recently been associ-
ated with fibrosis severity, and their hypoxemia severity
correlated with inflammation severity and increasing
NAS.(33)
IL-8 was also a significant discriminator of NASH
severity across multiple histologic components. It was
associated with fibrosis in overall multivariable analysis,
with NASH diagnosis in multivariable analysis exclud-
ing children with pediatric (Borderline Zone 1)
NASH, and with lobular inflammation in bivariate
analysis. IL-8 was also associated with fibrosis in the
adult NASH CRN cohort.(4) IL-8 is a proinflamma-
tory cytokine released from macrophages, endothe-
lium, and other cells and is primarily responsible for
recruiting neutrophils to sites of injury. Elevated IL-
8 levels have been associated with both NASH(34) and
alcoholic liver disease.(35) Lipid accumulation in hepa-
tocytes may induce production of IL-8.(36) IL-8 levels
were higher in children with hepatic steatosis measured
by magnetic resonance imaging in one study.(8)
IL-7 decreased with increasing fibrosis stage. IL-7
is generally considered a proinflammatory cytokine
secreted by adipose tissue as well as other cell types. In
high-fat-fed mice, IL-7 deficiency has been associated
with glucose intolerance.(37) An association of lower
IL-7 levels with higher fibrosis stage has been reported
in an adult NASH cohort(38) but does not seem to
have been investigated in pediatric NASH.
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Similarly, increased sIL-2Ra was associated with
fibrosis stage and with portal and lobular inflamma-
tion. It also emerged as a significant predictor of fibro-
sis in the adult NASH CRN cohort.(4) sIL-2Ra is a
marker of T-cell activation in the plasma. It is pro-
duced by T cells and then shed from their surface,
although its role as a mediator of inflammation is not
well characterized. Elevated sIL-2Ra levels have been
reported in patients with chronic hepatitis C(39) and
hepatocellular carcinoma.(40) In children, sIL-2Ra was
recently identified as a marker of poor prognosis in
pediatric acute liver failure, with levels significantly
higher in those children who died or required liver
transplantation.(41)
MMP-9 levels increased with portal inflammation
and any fibrosis but decreased with steatosis severity.
Elevated plasma MMP-9 has been reported in adults
with NASH compared to healthy controls(42) and with
viral hepatitis(43) but has not been studied in pediatric
subjects with NAFLD to our knowledge. MMP-9 lev-
els decreased in both obese children and adults with
OSA who were successfully treated, again suggesting
that hypoxia may play a role in NASH.(32) The pattern
of MMP-9 increase with inflammation and fibrosis but
decrease with steatosis severity is intriguing. In light of
theories that isolating free fatty acids in triglyceride
droplets, thereby increasing steatosis, may be protective
against NASH, the pattern we found suggests that
MMP-9 may be involved in NASH-mediated damage.
Additional analytes had associations with only one
histologic component, suggesting that they may play a
more targeted role in NASH. For example, IGF-II
and IL-1b emerged only in association with steatosis
severity. IGF-II is secreted primarily by hepatocytes
and is known to be involved in fetal pancreatic b-cell
development, but its role in children and adults is not
well characterized. Possibly related to its homology to
insulin and weak affinity for the insulin receptor, it
may play a role in glucose and fat metabolism.(44) Ele-
vations have been reported in obese individuals.(45)
Overexpression of IGF-II in mice leads to an increase
in pancreatic b-cell mass, insulin hypersecretion, insu-
lin resistance, and hepatic steatosis,(46,47) but an associ-
ation with hepatic steatosis in humans has not been
reported. Lower levels of IGF-II in children with
NAFLD fibrosis was recently observed but was not
associated with steatosis in a smaller cohort of obese
children(48) but was not observed in our study. Higher
levels of IGF-II with increased steatosis and lower lev-
els of IGF-II with advanced fibrosis and ballooning
were also seen in the adult NASH CRN cohort.(4)
A decrease in IL-1b was seen with increasing stea-
tosis in our cohort and in adult NASH in other
cohorts.(34,49) IL-1b is a proinflammatory cytokine
that appears to impact liver insulin sensitivity, with
lower levels associated with insulin resistance; higher
levels are profibrotic. IL-1b deficiency in mice pro-
tected against inflammation in mice with steatosis.(50)
One limitation of this study is that the cohort did
not include control subjects. Ideally, a control group
would include overweight pediatric patients with liver
biopsy available but without NAFLD or other liver
disease. Unfortunately, liver biopsies on this group of
children are rare for clinical purposes, and it is difficult
to justify the risk for research purposes. A control
group of nonoverweight children with liver biopsies
would not be directly applicable to NASH associations
because increased cytokine levels could reflect the low-
grade inflammation associated with obesity and insulin
resistance instead of just NASH.
Our cohort does explore the utility of plasma bio-
markers in differentiating severity of NAFLD and its
components among those with biopsy-proven fatty
liver disease. As a cross-sectional study, it identifies
correlations between analyte levels and NASH histol-
ogy. We relied on serum levels of analytes, so our anal-
yses do not identify the tissue driving cytokine levels,
i.e., adipose, muscle, liver, or other, or actual hepatic
levels. Additional longitudinal research of cytokines in
serum and liver or other tissues is warranted to investi-
gate the role of these analytes in differentiating
between those with and without NAFLD and in
NASH progression.
Another limitation of this study is that we examined
multiple plasma biomarkers and outcomes in these
analyses, increasing the risk of false-positive associa-
tions between plasma biomarkers and NASH. How-
ever, our analyte choices were hypothesis driven and
selected a priori based on their known role in processes
related to NASH. We have reported actual levels in
Supporting Tables S2-S4 so that the reader may put
the associations in context. Statistical analysis was
designed to minimize spurious associations by using
AIC minimization techniques to select predictors for
our multivariable models and competing the bio-
markers against established clinical discriminators of
NASH severity. Using AIC for model selection
allowed us to account for the large number of cytokines
evaluated while minimizing information lost in the
whittling of the model. It does not rely on statistical
significance from univariable analysis to choose predic-
tors for consideration in the multivariable models or on
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nested models, allowing more flexibility in considering
the contribution of each cytokine relative to the others.
However, AIC minimization is a relatively liberal tech-
nique as concerns predictor retention in final models;
our study intended to provide direction to future work
and not to definitively identify biomarkers ready for
clinical application.
Future investigations are needed to validate and
understand associations between the plasma bio-
markers and NASH histology identified in this analy-
sis. Of particular interest will be to study whether
changes in these biomarker levels correspond to
changes in NASH histology over time and to further
study their etiologic roles in NASH progression or
improvement and to assess whether any might prove
useful as noninvasive biomarkers. Correlation of base-
line biomarker levels with NASH progression may
potentially allow for prognostic testing at initial diag-
nosis. A central puzzle in pediatric NASH remains the
accurate prediction of which patients will progress to
cirrhosis and end-stage liver disease in adulthood; this
study highlights cytokines deserving of further explora-
tion as biomarkers.
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